Maria Grazia Lazzaroni, Liala Moschetti, Marta Breda, Franco Franceschini, Paolo Airò
{"title":"Long-term organ damage accrual and late mortality in systemic sclerosis.","authors":"Maria Grazia Lazzaroni, Liala Moschetti, Marta Breda, Franco Franceschini, Paolo Airò","doi":"10.55563/clinexprheumatol/2xiitt","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Progressive organ damage accrual in patients with systemic sclerosis (SSc) can be measured using the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI). We aimed to evaluate the long-term evolution of organ damage accrual in SSc patients with at least 10 years of follow-up, identifying clinical and laboratory features associated with moderate and severe damage, and the association of SCTC-DI with \"late mortality\" (death >10 years after diagnosis).</p><p><strong>Methods: </strong>In this single-centre retrospective study, patients with SSc were included when fulfilling the following characteristics: 1) a baseline visit corresponding to the time of diagnosis; 2) a minimum of 10 years of follow-up after diagnosis; 3) available follow-up visits at predefined timepoints.</p><p><strong>Results: </strong>In 253 patients included in the study, SCTC-DI progressively increased from the baseline to 10 years after diagnosis, with 34% of patients showing moderate or severe damage at this time point. During the follow-up, the SCTC-DI score was higher, and had a higher annual rise, in dcSSc patients than in lcSSc and in ACA-negative patients than in ACA+. Multivariable analyses identified dcSSc, lack of ACA, and the SCTC-DI scores at previous timepoints as independent variables associated with moderate or severe damage. In patients with \"late mortality\", as compared to surviving patients, the SCTC-DI score was demonstrated to be significantly higher at the baseline and at every timepoint, with a higher annual rise.</p><p><strong>Conclusions: </strong>Factors associated with damage accrual in SSc patients with long-term follow-up were identified. Higher SCTC-DI and higher SCTC-DI annual rise were associated with late mortality in SSc.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/2xiitt","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Progressive organ damage accrual in patients with systemic sclerosis (SSc) can be measured using the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI). We aimed to evaluate the long-term evolution of organ damage accrual in SSc patients with at least 10 years of follow-up, identifying clinical and laboratory features associated with moderate and severe damage, and the association of SCTC-DI with "late mortality" (death >10 years after diagnosis).
Methods: In this single-centre retrospective study, patients with SSc were included when fulfilling the following characteristics: 1) a baseline visit corresponding to the time of diagnosis; 2) a minimum of 10 years of follow-up after diagnosis; 3) available follow-up visits at predefined timepoints.
Results: In 253 patients included in the study, SCTC-DI progressively increased from the baseline to 10 years after diagnosis, with 34% of patients showing moderate or severe damage at this time point. During the follow-up, the SCTC-DI score was higher, and had a higher annual rise, in dcSSc patients than in lcSSc and in ACA-negative patients than in ACA+. Multivariable analyses identified dcSSc, lack of ACA, and the SCTC-DI scores at previous timepoints as independent variables associated with moderate or severe damage. In patients with "late mortality", as compared to surviving patients, the SCTC-DI score was demonstrated to be significantly higher at the baseline and at every timepoint, with a higher annual rise.
Conclusions: Factors associated with damage accrual in SSc patients with long-term follow-up were identified. Higher SCTC-DI and higher SCTC-DI annual rise were associated with late mortality in SSc.
期刊介绍:
Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.